Clinical outcomes of upadacitinib dose escalation in inflammatory bowel disease: A single-center retrospective cohort study

Table 2 Indications for off-label escalated dosing of upadacitinib

Reason for off-label escalated dosing	Number of patients
Symptoms	22
Endoscopic activity	19
Laboratory findings	3
Symptoms and endoscopic activity	5
Symptoms and laboratory findings	3
Endoscopic activity and laboratory findings	2
Symptoms, endoscopic activity, and laboratory findings	1
Imaging and laboratory findings	1

Categories represent mutually exclusive indications (n = 56 total patients); each patient is counted once based on the combination of clinical symptoms, endoscopic activity, imaging findings, and laboratory abnormalities prompting dose escalation.